Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 146 peer-reviewed journal articles Updated
Neuro-oncology

Understanding Your Glioblastoma Diagnosis

At a Glance

Glioblastoma is an aggressive, Grade 4 brain tumor that requires prompt, specialized care. While the diagnosis is serious, there is a well-established standard of treatment involving surgery, radiation, and chemotherapy, and care at a specialized center can improve outcomes.

Receiving a diagnosis of glioblastoma can feel like the world has shifted beneath your feet. It is natural to feel a sense of panic or overwhelming fear. However, understanding the landscape of this disease is the first step toward regaining a sense of control. Glioblastoma (GBM) is the most common type of malignant primary brain tumor in adults [1]. While it is an aggressive, fast-growing tumor, there is a well-established path forward and a dedicated medical community focused on your care.

Understanding the Disease

Glioblastoma is classified by the World Health Organization (WHO) as a Grade 4 tumor, meaning it is highly active and tends to spread into nearby brain tissue [2]. It most frequently affects adults between the ages of 49 and 56 and is slightly more common in men than women [3][4].

Because these tumors are located in the brain, they often cause neurologic symptoms such as headaches, seizures, or changes in speech and movement, depending on where the tumor is located [5][6]. Because the tumor grows quickly, the clinical course requires prompt and intensive medical intervention [7].

Important Things to Keep in Mind

In the early days following a diagnosis, it is helpful to anchor yourself with these three facts:

  1. There is a Clear Standard of Care: You do not have to guess what comes next. Doctors follow a rigorous, evidence-based protocol (often called the “Stupp Protocol”) that involves surgery, radiation, and chemotherapy [8][9].
  2. Understand the Statistics in Context: You will likely see online that the median survival for glioblastoma is between 12 and 15 months [10]. While this is a difficult reality to process, it is important to know that this is an average. Survival is highly dependent on your specific molecular markers, age, and treatment. Documented cases exist of patients living 14 years or more following treatment [11][12], and research shows that survival rates have been modestly but steadily improving [13].
  3. Modern Technology is on Your Side: Beyond traditional surgery and drugs, newer therapies like Tumor Treating Fields (TTFields)—wearable devices that use electric fields to disrupt tumor cell division—have been shown to significantly improve survival when used alongside chemotherapy [14][15].

Why Specialized Care Matters

Glioblastoma is complex and requires a level of expertise that “general” oncology centers may not possess. It is highly recommended that you seek care at a high-volume medical center for several reasons:

  • Superior Outcomes: Patients treated at high-volume centers—those that see many GBM cases each year—frequently experience better surgical results and postoperative outcomes [16].
  • The Tumor Board: Specialized centers use a Multidisciplinary Tumor Board (MTB). This is a team of experts—including neurosurgeons, neuro-oncologists, radiation oncologists, and pathologists—who meet to review your specific case and tailor a treatment plan to your unique tumor markers [17][18].
  • Precision and Clinical Trials: Specialized centers often have access to the most advanced tools, such as fluorescence-guided surgery (which helps surgeons see the tumor more clearly during operation) and early-phase clinical trials that may not be available elsewhere [19][20].

Guide Navigation

To fully understand your diagnosis and empower yourself for the journey ahead, explore the following pages in this guide:

01

Symptoms and the Diagnostic Process

Learn about glioblastoma (GBM) symptoms like headaches and seizures, and the diagnostic process. Understand MRIs, tissue biopsies, and genetic testing.

02

The Biology of Glioblastoma: The 2021 Standards

Learn how the 2021 WHO classification defines glioblastoma. Understand your pathology report, including IDH-wildtype, EGFR, and TERT molecular markers.

03

Auditing Your Pathology Report & Biomarkers

Learn how to read your glioblastoma pathology report. Understand key biomarkers like MGMT methylation, TERT, and EGFR to help guide your treatment options.

04

The Standard of Care for Glioblastoma

Learn the standard of care treatment for glioblastoma (GBM), including surgery, the Stupp Protocol, radiation, temozolomide, and Tumor Treating Fields.

05

Navigating Follow-Up: Pseudoprogression vs. True Recurrence

Learn how to tell pseudoprogression from true glioblastoma recurrence after treatment. Understand MRI results, advanced scans, and managing scanxiety.

06

Recurrence, Clinical Trials, and Advanced Care

Learn about treatment options for glioblastoma recurrence. Understand salvage surgery, re-irradiation, Bevacizumab, clinical trials, and palliative care.

07

Building Your Care Team & Preparing for the Journey

Learn how to build an expert glioblastoma care team. Find out which specialists you need, what to bring to your first appointment, and questions to ask.

Common questions in this guide

What is the standard treatment for a newly diagnosed glioblastoma?
The standard treatment for glioblastoma typically involves a coordinated approach of surgery followed by radiation and chemotherapy. This evidence-based protocol, often called the Stupp Protocol, provides a clear path forward for newly diagnosed patients.
Why is it important to be treated at a specialized glioblastoma center?
Specialized high-volume centers have multidisciplinary tumor boards that tailor treatments to your specific molecular markers. They also offer access to advanced tools like fluorescence-guided surgery and early-phase clinical trials, which often lead to better surgical outcomes.
What does it mean that glioblastoma is a Grade 4 tumor?
The World Health Organization classifies glioblastoma as a Grade 4 tumor, which means it is highly active and fast-growing. Because these tumors tend to spread into nearby brain tissue, they require prompt and intensive medical intervention.
Are Tumor Treating Fields (TTFields) used for glioblastoma?
Yes, Tumor Treating Fields (TTFields) are wearable devices that use mild electric fields to disrupt tumor cell division. Research shows they can significantly improve survival rates when used as a maintenance therapy alongside standard chemotherapy.
Should my glioblastoma case be reviewed by a tumor board?
Yes, it is highly recommended that your case is reviewed by a multidisciplinary neuro-oncology tumor board. This team of specialized neurosurgeons, oncologists, and pathologists works together to design a comprehensive treatment plan unique to your tumor's biology.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my case been reviewed by a dedicated multidisciplinary neuro-oncology tumor board?
  2. 2.What was the extent of my surgical resection—was a 'gross total resection' achieved?
  3. 3.Can you explain my MGMT promoter methylation and IDH mutation status and what they mean for my treatment?
  4. 4.Will I be prescribed Tumor Treating Fields (TTFields) as part of my maintenance therapy?
  5. 5.Does this hospital treat a high volume of glioblastoma patients annually?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Editorial for "Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells".

    Kolothara Unnikrishnan M, Schmidt MHH

    Cancers 2023; (15(15)) doi:10.3390/cancers15153830.

    PMID: 37568645
  2. 2

    The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV.

    Krigers A, Pinggera D, Demetz M, et al.

    Frontiers in neurology 2022; (13()):900377 doi:10.3389/fneur.2022.900377.

    PMID: 35785334
  3. 3

    Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.

    Paranthaman S, Goravinahalli Shivananjegowda M, Mahadev M, et al.

    Pharmaceutics 2020; (12(12)) doi:10.3390/pharmaceutics12121198.

    PMID: 33321953
  4. 4

    Glioblastoma 20 years after a nail gun trauma: A risk factor?

    Finneran MM, Young M, Joyce L, Nardone EM

    Clinical case reports 2022; (10(6)):e05927 doi:10.1002/ccr3.5927.

    PMID: 35662785
  5. 5

    Palliative Care in High-Grade Glioma: A Review.

    Crooms RC, Goldstein NE, Diamond EL, Vickrey BG

    Brain sciences 2020; (10(10)) doi:10.3390/brainsci10100723.

    PMID: 33066030
  6. 6

    Pre-Surgery Cognitive Performance and Voxel-Based Lesion-Symptom Mapping in Patients with Left High-Grade Glioma.

    Guarracino I, Ius T, Baiano C, et al.

    Cancers 2021; (13(6)) doi:10.3390/cancers13061467.

    PMID: 33806837
  7. 7

    Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

    Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, et al.

    Journal of neuro-oncology 2020; (147(2)):297-307 doi:10.1007/s11060-020-03451-6.

    PMID: 32157552
  8. 8

    Current state of immunotherapy for glioblastoma.

    Lim M, Xia Y, Bettegowda C, Weller M

    Nature reviews. Clinical oncology 2018; (15(7)):422-442 doi:10.1038/s41571-018-0003-5.

    PMID: 29643471
  9. 9

    Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature.

    Montemurro N

    Journal of neurological surgery. Part A, Central European neurosurgery 2020; (81(1)):64-70 doi:10.1055/s-0039-1688911.

    PMID: 31550738
  10. 10

    Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).

    Khabibov M, Garifullin A, Boumber Y, et al.

    International journal of oncology 2022; (60(6)).

    PMID: 35445737
  11. 11

    Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series.

    Gesundheit B, Ben-David E, Posen Y, et al.

    Frontiers in oncology 2020; (10()):702 doi:10.3389/fonc.2020.00702.

    PMID: 32477944
  12. 12

    Survival of a patient with glioblastoma multiforme after undergoing bone flap surgery followed by chemoradiotherapy to maintain tumor-treating fields: A case report.

    Yang H, Wang L, Zheng J, et al.

    The Journal of international medical research 2025; (53(6)):3000605251343020 doi:10.1177/03000605251343020.

    PMID: 40470784
  13. 13

    Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013.

    Zreik J, Moinuddin FM, Yolcu YU, et al.

    Journal of neuro-oncology 2020; (148(1)):69-79 doi:10.1007/s11060-020-03469-w.

    PMID: 32363470
  14. 14

    Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma.

    Shah S, Nag A, Lucke-Wold B

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025; (27(7)):2904-2912 doi:10.1007/s12094-025-03849-6.

    PMID: 39893330
  15. 15

    Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.

    Ballo MT, Conlon P, Lavy-Shahaf G, et al.

    Journal of neuro-oncology 2023; (164(1)):1-9 doi:10.1007/s11060-023-04348-w.

    PMID: 37493865
  16. 16

    The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma.

    Lopez Ramos C, Brandel MG, Steinberg JA, et al.

    Journal of neuro-oncology 2019; (141(1)):159-166 doi:10.1007/s11060-018-03022-w.

    PMID: 30460629
  17. 17

    Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.

    Kuehn JC, Metzger P, Neidert N, et al.

    NPJ precision oncology 2024; (8(1)):180 doi:10.1038/s41698-024-00674-y.

    PMID: 39143272
  18. 18

    Do Multidisciplinary Tumor Board Discussions Correlate With Increase in 5-Year Survival? A Meta-Analysis Study.

    Algwaiz G, Salam Y, Bustami R, et al.

    Global journal on quality and safety in healthcare 2021; (4(1)):3-10 doi:10.36401/JQSH-20-23.

    PMID: 37260532
  19. 19

    5-aminolevulinic enhanced brain lesions mimic glioblastoma: A case report and literature review.

    Chang CY, Chen CC

    Medicine 2024; (103(1)):e34518 doi:10.1097/MD.0000000000034518.

    PMID: 38181251
  20. 20

    Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.

    Valerius AR, Webb LM, Thomsen A, et al.

    International journal of molecular sciences 2024; (25(19)) doi:10.3390/ijms251910570.

    PMID: 39408897

This page provides a general overview of a glioblastoma diagnosis for educational purposes. Always consult a specialized neuro-oncology team regarding your specific prognosis and treatment plan.

Get notified when new evidence is published on Glioblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.